Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Yulian Khagi(Center for Personalized Cancer Treatment), Razelle Kurzrock(Medical College of Wisconsin), Assuntina G. Sacco(University of California San Diego), Sandip Pravin Patel(University of California San Diego), Aaron M. Goodman(University of California San Diego), Gregory A. Daniels(University of California San Diego), James M. Randall(University of California San Diego), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center)
Cited by 202
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancerdiagnostic approach
|Nature|2020|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k